68Ga-Trivehexin PET/CT in Metastatic Non-Small Cell Lung Cancer to the Brain.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
28 Aug 2024
28 Aug 2024
Historique:
medline:
27
8
2024
pubmed:
27
8
2024
entrez:
27
8
2024
Statut:
aheadofprint
Résumé
In the era of molecular imaging and eager to study tumor tissues' microenvironment with noninvasive means, the search and development of new radiotracer targeted molecule continue. αvβ6-Integrin is a heterodimeric glycoprotein transmembrane receptor that is unique in that it is expressed exclusively in epithelial cells. It is upregulated in varieties of carcinomas such of the lung, breast, and colon. It plays a role in facilitating invasion, inhibiting apoptosis, regulating expression of matrix metalloproteases, and activating TGF-β in carcinoma. Expression of αvβ6 indicates poor prognosis and can help in development of targeted therapy. 68Ga-Trivehexin has affinity of 85%-88% of this integrin.
Identifiants
pubmed: 39190399
doi: 10.1097/RLU.0000000000005406
pii: 00003072-990000000-01255
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Dong X, Hudson NE, Lu C, et al. Structural determinants of integrin β-subunit specificity for latent TGF-β. Nat Struct Mol Biol. 2014;21:1091–1096.
Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376:354–366.
Thakral P, Das SS, Dhiman S, et al. Validation of in-house kit-like synthesis of 68Ga-Trivehexin and its biodistribution for targeting the integrin αvβ6 expressing tumors. Cancer Biother Radiopharm. 2023;38:468–474.
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024 [published correction appears in CA Cancer J Clin. 2024 Feb 16]. CA Cancer J Clin. 2024;74:12–49.
Elayadi AN, Samli KN, Prudkin L, et al. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res. 2007;67:5889–5895.
Yan P, Zhu H, Yin L, et al. Integrin αvβ6 promotes lung cancer proliferation and metastasis through upregulation of IL-8-mediated MAPK/ERK signaling. Transl Oncol. 2018;11:619–627.
Fan D, Zhang C, Luo Q, et al. In vivo evaluation of integrin αvβ6-targeting peptide in NSCLC and brain metastasis. Front Oncol. 2023;13:1070967.
Huynh TT, Sreekumar S, Mpoy C, et al. Therapeutic efficacy of 177Lu-labeled A20FMDV2 peptides targeting ανβ6. Pharmaceuticals (Basel). 2022;15:229.
Ganguly T, Bauer N, Davis RA, et al. Preclinical evaluation of 68Ga- and 177Lu-labeled integrin αvβ6-targeting radiotheranostic peptides. J Nucl Med. 2023;64:639–644.